BioPharma Dive20h
‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public
Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...
Bio-Rad targets 1.5%-3.5% revenue growth in 2025 amid operational improvements and new acquisitions
Bio-Rad projects 2025 currency-neutral revenue growth of 1.5%-3.5%, excluding contributions from acquisitions. Diagnostics revenue is expected to grow between 2%-3%, while Life Science revenue is ...
Bio-Rad reports Q4 adjusted EPS $2.90, consensus $2.88
Reports Q4 revenue $667.5M, consensus $679.75M. Norman Schwartz, Bio-Rad’s (BIO) Chairman and CEO, commented: “Bio-Rad demonstrated ...
healthcarepackaging2d
The Many Facets of Sustainable and Recyclable Blister Packaging for Pharmaceuticals Primary Packaging
Exploring sustainable blister packaging from the lens of material selection, quality regulations, machinability, and ...
Le Lézard3d
GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ® Gene Therapy at the Conclusion of the REFLECT Study
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative ...
SandboxAQ Expands Alliance with Deloitte to Offer AI Simulation Software Solutions
SandboxAQ today announced it has expanded its relationship with Deloitte to offer SandboxAQ's AI LQM simulation products and solutions along with Deloitte's services capabilities to organizations ...